



## Horizon Therapeutics to Participate in Upcoming Investor Conferences

May 19, 2020

DUBLIN, Ireland--(BUSINESS WIRE)--May 19, 2020-- Horizon Therapeutics (Nasdaq: HZNP) today announced that the Company will participate in the following upcoming conferences:

### ***Jefferies 2020 Virtual Healthcare Conference***

- Date: Tuesday, June 2

### ***BMO 2020 Prescriptions for Success Healthcare Conference (Virtual)***

- Date: Tuesday, June 23

The conference presentations will be webcast live and may be accessed by visiting Horizon's website at <http://ir.horizontherapeutics.com>. A replay of the webcasts will be available for the events.

### **About Horizon**

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit [www.horizontherapeutics.com](http://www.horizontherapeutics.com) and follow us on [Twitter](#), [LinkedIn](#), [Instagram](#) and [Facebook](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200519005154/en/): <https://www.businesswire.com/news/home/20200519005154/en/>

### **Investors:**

Tina Ventura  
Senior Vice President,  
Investor Relations  
[investor-relations@horizontherapeutics.com](mailto:investor-relations@horizontherapeutics.com)

Ruth Venning  
Executive Director,  
Investor Relations  
[investor-relations@horizontherapeutics.com](mailto:investor-relations@horizontherapeutics.com)

### **U.S. Media:**

Geoff Curtis  
Executive Vice President,  
Corporate Affairs & Chief Communications Officer  
[media@horizontherapeutics.com](mailto:media@horizontherapeutics.com)

### **Ireland Media:**

Ray Gordon  
Gordon MRM  
[ray@gordonmrm.ie](mailto:ray@gordonmrm.ie)

Source: Horizon Therapeutics